Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Rintatolimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AIM ImmunoTech Wins Japan Patent For Ampligen Combo Therapy
    AIM ImmunoTech Wins Japan Patent For Ampligen Combo Therapy

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258177/29489/en/AIM-ImmunoTech-Announces-Final-Approval-of-Novel-Cancer-Therapy-Patent-in-Japan-Combining-Ampligen-with-Checkpoint-Inhibitors.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    AIM ImmunoTech Announces Closing of its Rights Offering
    AIM ImmunoTech Announces Closing of its Rights Offering

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/07/3251368/29489/en/AIM-ImmunoTech-Announces-Closing-of-its-Rights-Offering.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal
    AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247438/29489/en/AIM-ImmunoTech-Signs-Agreement-for-Planning-of-a-Proposed-Phase-3-Clinical-Trial-of-Ampligen-in-the-Treatment-of-Late-Stage-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    AIM ImmunoTech Reminds Stockholders of March 3, 2026
    AIM ImmunoTech Reminds Stockholders of March 3, 2026

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246545/29489/en/AIM-ImmunoTech-Reminds-Stockholders-of-March-3-2026-Expiration-Date-and-Updates-Terms-of-Previously-Announced-Rights-Offering.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    AIM ImmunoTech Announces Commencement of Rights Offering
    AIM ImmunoTech Announces Commencement of Rights Offering

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237727/29489/en/CORRECTION-AIM-ImmunoTech-Announces-Commencement-of-Rights-Offering.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    AIM Immunotech Joins Virtual Investor Closing Bell Event
    AIM Immunotech Joins Virtual Investor Closing Bell Event

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237225/29489/en/AIM-ImmunoTech-to-Participate-in-Live-Virtual-Investor-Closing-Bell-Event.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.